Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...
Alligator Bioscience to Host Conference Call to Provide Full Year Report 2017 Business Update
Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 16 February 2018, at 08:00 am CET, Alligator Bioscience will publish its report fo ...
Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study
Lund, Sweden, 25 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...
Alligator Bioscience appoints new VP Business Development
Lund, Sweden, 18 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...
Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference
Lund, Sweden, 4 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunother ...
Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Alligator Bioscience expands management team
Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...
Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017
Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...